Quality Control Method for Vonoprazan Fumarate Intermediates
Through high performance liquid chromatography and gradient elution procedures, combined with specific mobile phase and chromatographic column conditions, the gap in the quality control of vonorapine fumarate in the prior art was solved, and the intermediate and its The high sensitivity and accurate quality control of impurities ensure the stability and safety of product quality.
Patent Information
- Application Number
- CN202211252968.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-13
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-10-13
AI Technical Summary
The prior art lacks effective quality control methods to monitor the preparation process and product quality of vonorazine fumarate intermediates, resulting in the incorporation of impurities that may affect the quality and safety of the final product.
Using high performance liquid chromatography, using aqueous trifluoroacetic acid solution and acetonitrile-tetrahydrofuran mixed solution as mobile phase, the intermediate voltage of fumarate was achieved through gradient elution procedure, combined with UV absorption detector and specific chromatographic column conditions. High sensitivity and accurate quality control of body and its impurities.
Effective quality control of vonorazoic fumarate intermediates is achieved, and the impurity separation ability and product quality stability during the preparation process is achieved. The detection sensitivity reaches a level of 100 nanomolar concentration, which is in line with the verification of quality analysis methods. Require.
Smart Images

Figure CN115656360B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a quality control method for a vonoprazan fumarate intermediate, and in particular to a quality control method capable of effectively monitoring the quality of the vonoprazan fumarate intermediate. Background Art
[0002] Vonoprazan fumarate (TAK-438) is a new oral anti-gastric acid drug developed by Takeda Pharmaceutical and Otsuka Pharmaceutical. 5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrole-3-carboxaldehyde is the key intermediate in the preparation of this raw material. Its CAS number is 881677-11-8 and its molecular formula is C 16 H 11 FN 2 O 3 S, molecular weight is 330.33, chemical structure is as follows:
[0003]
[0004] The impurities such as process by-products and degradation products generated during the preparation of the above intermediates mainly include the following four types:
[0005]
[0006] The above impurities can be introduced into the API or preparations through the subsequent process flow, which will directly affect the quality, safety and effectiveness of the final product. Therefore, it is necessary to monitor the preparation process and product quality of the above vonoprazan fumarate intermediates, and there is currently no relevant quality control method. Summary of the invention
[0007] Purpose of the invention: In view of the gap in the quality control of the above-mentioned vonoprazan fumarate intermediate in the existing detection methods, the present invention aims to provide an effective, stable and reliable quality control method for the intermediate.
[0008] Technical solution: The quality control method of the vonoprazan fumarate intermediate having the following structure of the present invention is as follows:
[0009]
[0010] The invention adopts high performance liquid chromatography, uses trifluoroacetic acid aqueous solution as mobile phase A, uses acetonitrile-tetrahydrofuran mixed solution as mobile phase B, and performs gradient elution; the elution program comprises: from 0 to 36 minutes, the volume fraction of mobile phase A decreases from 90 to 80% to 40 to 50%, and the volume fraction of mobile phase B increases from 10 to 20% to 50 to 60%.
[0011] Specifically, the quality control impurities are as follows:
[0012]
[0013] Wherein, the volume percentage of trifluoroacetic acid in the above-mentioned mobile phase A is 0.02% to 0.1%, and the volume ratio of acetonitrile to tetrahydrofuran in the mobile phase B is 30:70 to 40:60; preferably, the volume percentage of trifluoroacetic acid in the mobile phase A is 0.04%, and the volume ratio of acetonitrile to tetrahydrofuran in the mobile phase B is 35:65.
[0014] Furthermore, the elution procedure comprises: from 0 to 36 min, the volume fraction of mobile phase A decreases from 85% to 45%, and the volume fraction of mobile phase B increases from 15% to 55%; further, the above elution gradient is preferably as follows:
[0015]
[0016] A more preferred elution gradient is as follows:
[0017]
[0018] Among them, the above-mentioned chromatographic column uses octadecylsilane bonded silica gel as the filling phase, the detector is an ultraviolet absorption detector, the detection wavelength is 225nm~235nm, the column temperature is 35℃~45℃, and the mobile phase flow rate is 0.5ml / min~1.0ml / min; further, the preferred specifications of the above-mentioned chromatographic column are 4.6mm×150mm, the filler particle size is 3μm, the specific chromatographic column used is YMC-Triart C18 ExRs column, the detection wavelength is 230nm, the column temperature is 40℃, the mobile phase flow rate is 0.6ml / min~0.8ml / min, and more preferably 0.65ml / min~0.7ml / min.
[0019] The quality control method of the above-mentioned vonoprazan fumarate intermediate specifically comprises the following steps:
[0020] (1) Prepare test sample solution and system suitability solution;
[0021] (2) Setting the detection conditions: using high performance liquid chromatography, the detector is an ultraviolet absorption detector, the detection wavelength is 225m-235nm, the column temperature is 30°C-45°C, the method uses a chromatographic column with octadecylsilane bonded silica gel as a filler, the mobile phase A is a trifluoroacetic acid aqueous solution; the mobile phase B is an acetonitrile-tetrahydrofuran mixed solution, gradient elution is used, and the mobile phase flow rate is 0.5ml / min-1.0ml / min;
[0022] (3) Take the test solution and system suitability solution separately, inject them into the high performance liquid chromatography for detection and analysis.
[0023] The test solution is prepared by accurately weighing an appropriate amount of the vonoprazan fumarate intermediate, adding a diluent to dissolve and dilute the solution to form a solution containing about 0.4 mg / ml of the vonoprazan fumarate intermediate;
[0024] The method for preparing the system suitability solution is to take appropriate amounts of impurity A, impurity B, impurity C, impurity D and vonoprazan fumarate intermediate reference substance, add solvent to dissolve and dilute to make a mixed solution containing approximately vonoprazan fumarate intermediate: 0.4 mg, impurity A: 8 μg, and other impurities: 4 μg each per 1 ml.
[0025] Wherein, the diluent is acetonitrile.
[0026] Furthermore, the linear range of the above quality control method for each quality control component is as follows:
[0027]
[0028]
[0029] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages:
[0030] 1. The method has strong specificity (it can effectively separate intermediates and various impurities), high detection sensitivity (reaching the level of 100 nanomolar concentration), stability and reliability (meeting the requirements of quality analysis methodology validation), and can be used for the preparation process of vonoprazan fumarate intermediates and the monitoring of product quality;
[0031] 2. By optimizing the detection conditions, the YMC-Triart C18 ExRs column and tetrahydrofuran were used to improve the separation ability between structural isomers. At the same time, acetonitrile was used to improve the peak shape, realizing highly sensitive and accurate qualitative and quantitative research on various impurities in vonoprazan fumarate intermediates. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 The chromatogram of the separation solution in Example 1;
[0033] Figure 2 is the chromatogram of the blank solution in Example 2;
[0034] Figure 3 is the chromatogram of the system suitability solution in Example 2;
[0035] Figure 4 It is the chromatogram of the test solution in Example 2;
[0036] Figure 5 The chromatogram of the separation solution in Comparative Example 1;
[0037] Figure 6The chromatogram is the original image of the separation solution investigation in Comparative Example 2;
[0038] Figure 7 The chromatogram is an enlarged coordinate axis of the separation solution in Comparative Example 2;
[0039] Figure 8 The chromatogram of the separation solution in Comparative Example 3 is as follows;
[0040] Fig. 9 The chromatogram of the separation solution in Comparative Example 4 is as follows;
[0041] Fig.10 This is the chromatogram of the separation solution investigated in Comparative Example 5. DETAILED DESCRIPTION
[0042] The technical solution of the present invention is further described below in conjunction with embodiments.
[0043] Example 1: Determination of detection method
[0044] The diluent in the preparation of the resolution solution is acetonitrile.
[0045] Separation solution: Take appropriate amounts of impurity A, impurity B, impurity C, impurity D and vonoprazan fumarate intermediate reference substance, add solvent to dissolve and dilute to prepare a mixed solution containing approximately 0.4 mg of vonoprazan fumarate intermediate and 2 μg of each impurity per 1 ml.
[0046] The chromatographic detection conditions are as follows:
[0047] The chromatographic column was YMC-Triart C18 ExRs, 4.6 mm × 150 mm, 3 μm, the column temperature was 40 °C, the mobile phase A was 0.04% trifluoroacetic acid solution, the mobile phase B was acetonitrile-tetrahydrofuran (35:65, V / V), and the flow rate and gradient were as follows:
[0048]
[0049] Injection volume: 5μl, detection wavelength is 230nm, take the separation solution for injection.
[0050] Experimental results: The separation of impurity peaks is shown in Figure 1 The separation degrees of the four impurities are all greater than 1.5, and the peaks are sharp.
[0051] Example 2: Determination of Related Substances of Vonoprazan Fumarate Intermediates
[0052] (1) HPLC conditions
[0053] Octadecylsilane silica gel was used as filler (YMC-Triart C18 ExRs, 4.6 mm × 150 mm, 3 μm or a chromatographic column with equivalent performance); 0.04% trifluoroacetic acid solution was used as mobile phase A, acetonitrile-tetrahydrofuran (35:65) was used as mobile phase B, and linear gradient elution was performed according to Table 1; the column temperature was 40°C; the detection wavelength was 230 nm; and the injection volume was 5 μl.
[0054] Table 1. Flow rate and gradient
[0055]
[0056] (2) Solution preparation
[0057] Solvent: Acetonitrile
[0058] Test solution: Take an appropriate amount of vonoprazan fumarate intermediate, dissolve it in solvent and dilute it to make a solution containing about 0.4 mg per 1 ml.
[0059] System suitability solution: Take appropriate amounts of impurity A, impurity B, impurity C, impurity D and vonoprazan fumarate intermediate reference substance, add solvent to dissolve and dilute to make a mixed solution containing approximately vonoprazan fumarate intermediate: 0.4 mg, impurity A: 8 μg, and other impurities: 4 μg each per 1 ml.
[0060] Accurately take 5 μl of the test solution and system suitability solution, inject them into the liquid chromatograph, and record the chromatogram. If there are impurity peaks in the chromatogram of the test solution, calculate the impurity content by the peak area normalization method with the correction factor added. Any impurity peaks less than 0.03% in the chromatogram of the test solution are ignored.
[0061] (3) System applicability investigation
[0062] Prepare blank solution, system suitability solution and test solution according to the above method in the examples for determination. Figure 2 , Figure 3 , Figure 4 The results show that, using the chromatographic conditions of the present invention, the blank solution has no interference, and the main component and impurities as well as the impurities can be effectively separated, indicating that the system applicability of this method is good.
[0063] (4) Sensitivity test
[0064] The main component (fumarate vonoprazan intermediate) reference substance and impurity reference substance stock solution were prepared according to the method in the embodiment, and the appropriate amount of each impurity reference substance stock solution was accurately measured, and the diluent was gradually diluted and determined, and the signal-to-noise ratio was about 10:1 as the quantitative limit to investigate the detection sensitivity of each impurity. The results are shown in Table 2. The results show that the sensitivity of this method is good.
[0065] Table 2. Sensitivity test results
[0066]
[0067] (5) Linear investigation
[0068] The main component (fumarate vonoprazan intermediate) reference substance and impurity reference substance stock solution were prepared according to the method in the embodiment, and the appropriate amount of each impurity reference substance stock solution was accurately measured, and a series of concentrations were diluted with a diluent to form a linear solution of each component. The test results are shown in Table 3 below. The results show that the linear relationship of each component to be tested is good using the chromatographic conditions of the present invention.
[0069] Table 3. Linearity test results
[0070]
[0071]
[0072] (6) Correction factor
[0073] The calibration factor was determined using the standard curve method and the results are shown in Table 4.
[0074] Table 4. Correction factors
[0075]
[0076] (7) Solution stability study
[0077] At different times, 5 μl of the system suitability solution and the test solution were injected into the liquid chromatograph, and the chromatograms were recorded. The results are shown in Tables 5 and 6. The test solution was measured at room temperature at 0h, 2h, 5.5h, 24h, 46h, and 48h. The difference between the corresponding impurity detection amount of the test solution at each time point and that at 0h was ≤0.05%; no new impurities ≥0.03% appeared. It shows that the test solution is stable for at least 48h at room temperature. The system suitability solution was measured at room temperature at 0h, 3h, 27h, 25h, 36.5h, 43h, and 51.5h. At each time point, the ratio of the peak area of each impurity peak in the system suitability solution to the peak area of 0h was between 80% and 120%. It shows that the system suitability solution is stable for at least 51.5h at room temperature.
[0078] Table 5. Stability test of related substances solution - test solution
[0079]
[0080] Table 6. Related substance solution stability test - system suitability
[0081]
[0082] (8) Accuracy test
[0083] Accurately weigh 9 portions of vonoprazan fumarate samples, add impurity reference solutions with impurity limits of 50%, 100%, and 150%, respectively, add diluent to dissolve and dilute to the scale, as test solutions. Accurately measure each test solution and dilute 1000 times as a control solution. Accurately measure 5μl of the above test solution and control solution and inject them into the liquid chromatograph, record the chromatogram, and calculate the recovery rate of each impurity [(measured amount-background amount) / added amount]. The results are shown in Table 7. The results show that the recovery rates of each impurity are between 80% and 120%, and the RSD is less than 10.0%, indicating that this method has good accuracy and is suitable for the detection of related substances of this product.
[0084] Table 7. Accuracy calculation table
[0085]
[0086]
[0087] In summary, the quality control method of the vonoprazan fumarate intermediate of the present invention has strong specificity, high sensitivity, good linear relationship and high accuracy.
[0088] Comparative Example 1
[0089] The diluent in the preparation of the resolution solution is acetonitrile.
[0090] Separation solution: Take appropriate amounts of impurity A, impurity B, impurity C, impurity D and vonoprazan fumarate intermediate reference substance, add solvent to dissolve and dilute to prepare a mixed solution containing approximately 0.4 mg of vonoprazan fumarate intermediate and 2 μg of each impurity per 1 ml.
[0091] The chromatographic detection conditions are as follows:
[0092] The detection wavelength was 230 nm, the chromatographic column was YMC ODS-A 4.6 mm × 150 mm, 5 μm, the column temperature was 35 ° C, the flow rate was 0.7 ml / min, the mobile phase A was 0.1% trifluoroacetic acid solution, the mobile phase B was methanol, and the gradient was as follows:
[0093]
[0094] Injection volume: 5μl, detection wavelength is 230nm, take the separation solution for injection.
[0095] Take the separation solution and inject it. The experimental results are as follows: Figure 5 , all the impurities are wrapped in the main peak, and the peak shape of the main component is poor.
[0096] Comparative Example 2
[0097] The diluent in the preparation of the resolution solution is acetonitrile.
[0098] Separation solution: Take appropriate amounts of impurity A, impurity B, impurity C, impurity D and vonoprazan fumarate intermediate reference substance, add solvent to dissolve and dilute to prepare a mixed solution containing approximately 0.4 mg of vonoprazan fumarate intermediate and 2 μg of each impurity per 1 ml.
[0099] The chromatographic detection conditions are as follows:
[0100] The chromatographic column was YMC ODS-A 4.6 mm × 150 mm, 5 μm, the column temperature was 35 °C, the flow rate was 0.7 ml / min, the mobile phase A was 0.1% trifluoroacetic acid solution, the mobile phase B was acetonitrile, and the gradient was as follows:
[0101]
[0102] Injection volume: 5μl, detection wavelength is 230nm, take the separation solution for injection.
[0103] Experimental results: The main component peak shape is shown in Figure 6 , see Figure 7 , the peak shape of the main component improved, and impurity C and impurity D were not separated.
[0104] Comparative Example 3
[0105] The diluent in the preparation of the resolution solution is acetonitrile.
[0106] Separation solution: Take appropriate amounts of impurity A, impurity B, impurity C, impurity D and vonoprazan fumarate intermediate reference substance, add solvent to dissolve and dilute to prepare a mixed solution containing approximately 0.4 mg of vonoprazan fumarate intermediate and 2 μg of each impurity per 1 ml.
[0107] The chromatographic detection conditions are as follows:
[0108] The chromatographic column was YMC ODS-A 4.6 mm × 150 mm, 5 μm, the column temperature was 35 ° C, the flow rate was 0.7 ml / min, the mobile phase A was 0.1% trifluoroacetic acid solution, the mobile phase B was acetonitrile-tetrahydrofuran (80:20, V / V), and the gradient was as follows:
[0109]
[0110] Injection volume: 5μl, detection wavelength is 230nm, take the separation solution for injection.
[0111] Experimental results: The separation of impurity peaks is shown in Figure 8 , impurity C and impurity D are not separated.
[0112] Comparative Example 4
[0113] The diluent in the preparation of the resolution solution is acetonitrile.
[0114] Separation solution: Take appropriate amounts of impurity A, impurity B, impurity C, impurity D and vonoprazan fumarate intermediate reference substance, add solvent to dissolve and dilute to prepare a mixed solution containing approximately 0.4 mg of vonoprazan fumarate intermediate and 2 μg of each impurity per 1 ml.
[0115] The chromatographic detection conditions are as follows:
[0116] The chromatographic column was YMC ODS-A 4.6 mm × 150 mm, 5 μm, the column temperature was 35 ° C, the flow rate was 0.7 ml / min, the mobile phase A was 0.1% trifluoroacetic acid solution, the mobile phase B was acetonitrile-tetrahydrofuran (40:60, V / V), and the gradient was as follows:
[0117]
[0118] Injection volume: 5μl, detection wavelength is 230nm, take the separation solution for injection.
[0119] Experimental results: The separation of impurity peaks is shown in Fig. 9 , the separation degree of impurity C and impurity D increased, but they were not baseline separated.
[0120] Comparative Example 5
[0121] The diluent in the preparation of the resolution solution is acetonitrile.
[0122] Separation solution: Take appropriate amounts of impurity A, impurity B, impurity C, impurity D and vonoprazan fumarate intermediate reference substance, add solvent to dissolve and dilute to prepare a mixed solution containing approximately 0.4 mg of vonoprazan fumarate intermediate and 2 μg of each impurity per 1 ml.
[0123] The chromatographic detection conditions are as follows:
[0124] The chromatographic column was YMC-Triart C18 ExRs, 4.6 mm × 150 mm, 3 μm, the column temperature was 35 °C, the flow rate was 0.5 ml / min, the mobile phase A was 0.1% trifluoroacetic acid solution, the mobile phase B was acetonitrile-tetrahydrofuran (40:60, V / V), and the gradient was as follows:
[0125]
[0126] Injection volume: 5μl, detection wavelength is 230nm, take the separation solution for injection.
[0127] Experimental results: The separation of impurity peaks is shown in Fig.10, the separation degree between impurity C and impurity D increases, the separation degree is greater than 1.5, but the peak is very blunt and the theoretical plate number is not high.
Claims
1. A quality control method for a vonoprazan fumarate intermediate having the following structure: It is characterized in that Its quality control impurities are as follows: The method adopts a high performance liquid chromatography method, an octadecylsilane bonded silica gel phase chromatography column, a detector is an ultraviolet absorption detector, a detection wavelength is 225nm-235nm, a trifluoroacetic acid aqueous solution is used as a mobile phase A, and an acetonitrile-tetrahydrofuran mixed solution is used as a mobile phase B, and gradient elution is performed; the volume percentage of trifluoroacetic acid in the mobile phase A is 0.04%, and the volume ratio of acetonitrile to tetrahydrofuran in the mobile phase B is 35:65; The elution gradient is as follows:
2. The quality control method according to claim 1, characterized in that: The column temperature of the chromatographic column is 35° C. to 45° C., and the flow rate of the mobile phase is 0.5 ml / min to 1.0 ml / min.
3. The quality control method according to claim 2, characterized in that: The specification of the chromatographic column is 4.6 mm×150 mm, the filler particle size is 3 μm, the detection wavelength is 230 nm, the column temperature is 40° C., and the mobile phase flow rate is 0.6 ml / min to 0.8 ml / min.
4. The quality control method according to claim 3, characterized in that: The chromatographic column is a YMC-Triart C18ExRs column.
5. The quality control method according to claim 3, characterized in that: The flow rate of the mobile phase is 0.65ml / min to 0.7ml / min.
6. The quality control method according to claim 1, characterized in that: The elution gradient is as follows:
7. The quality control method according to claim 1, characterized in that: The detection linear range of each quality control component is as follows:
8. The quality control method according to claim 7, characterized in that: The linear equations of the concentration of each quality control component and the chromatographic peak area are as follows: Wherein, x is the concentration of each quality control component, and y is the chromatographic peak area of each quality control component corresponding to x.
9. The quality control method according to claim 1, characterized in that: The steps include: (1) Prepare test sample solution and system suitability solution; (2) Setting the test conditions; (3) Take the test solution and system suitability solution separately, inject them into the high performance liquid chromatograph for detection and analysis; The preparation method of the test solution is to accurately weigh an appropriate amount of the vonoprazan fumarate intermediate, add a diluent to dissolve and dilute it into a solution containing 0.4 mg / ml of the vonoprazan fumarate intermediate; The method for preparing the system suitability solution is to take appropriate amounts of impurity A, impurity B, impurity C, impurity D and vonoprazan fumarate intermediate reference substance, add diluent to dissolve and dilute to prepare a mixed solution containing vonoprazan fumarate intermediate: 0.4 mg, impurity A: 8 μg, and other impurities: 4 μg each per 1 ml; The diluent was acetonitrile.
